-
Subgroup analysis of steadily increased trends in medullary thyroid carcinoma incidence and mortality in the USA, 2000–2020: a population-based retrospective cohort study Endocr. Relat. Cancer (IF 3.9) Pub Date : 2024-05-01 Zixia Tao, Xianzhao Deng, Bomin Guo, Zheng Ding, Youben Fan
The incidence rate of medullary thyroid carcinoma (MTC) continues to grow, along with its mortality rate in the USA. However, the subgroup trends in MTC have not yet been established. This population-based retrospective cohort study was based on the Surveillance, Epidemiology, and End Results (SEER) 17/12 registry database. Subgroup analysis was performed through clinicopathological and treatment-related
-
Multivariable model versus AJCC staging system: cancer-specific survival predictions in adrenocortical carcinoma Endocr. Relat. Cancer (IF 3.9) Pub Date : 2024-04-01 Letizia Maria Ippolita Jannello, Simone Morra, Lukas Scheipner, Andrea Baudo, Carolin Siech, Mario de Angelis, Nawar Touma, Zhe Tian, Jordan A Goyal, Stefano Luzzago, Francesco A Mistretta, Mattia Luca Piccinelli, Fred Saad, Felix K H Chun, Alberto Briganti, Sascha Ahyai, Luca Carmignani, Nicola Longo, Ottavio de Cobelli, Gennaro Musi, Pierre I Karakiewicz
We developed a novel contemporary population-based model for predicting cancer-specific survival (CSS) in adrenocortical carcinoma (ACC) patients and compared it with the established 8th edition of the American Joint Committee on Cancer staging system (AJCC). Within the Surveillance, Epidemiology, and End Results database (2004–2020), we identified 1056 ACC patients. Univariable Cox regression model
-
Letter to the editor: Clinical and basic research implications of the article "IGF-1 Axis changes with ADT and docetaxel in metastatic prostate cancer" Endocr. Relat. Cancer (IF 3.9) Pub Date : 2024-03-01 Isabel Heidegger, Zoran Culig
letter to the editor- no abstract
-
Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms Endocr. Relat. Cancer (IF 3.9) Pub Date : 2024-04-01 Darren Cowzer, Ronak H Shah, Joanne F Chou, Ritika Kundra, Sippy Punn, Laura Fiedler, April DeMore, Marinela Capanu, Michael F Berger, Diane Reidy-Lagunes, Nitya Raj
In advanced pancreatic neuroendocrine neoplasms (PanNEN), there are little data detailing the frequency of genetic alterations identified in cell free DNA (cfDNA), plasma–tissue concordance of detected alterations, and clinical utility of cfDNA. Patients with metastatic PanNENs underwent cfDNA collection in routine practice. Next-generation sequencing (NGS) of cfDNA and matched tissue when available
-
Transformation of G1-G2 neuroendocrine tumors to neuroendocrine carcinomas following peptide receptor radionuclide therapy Endocr. Relat. Cancer (IF 3.9) Pub Date : 2024-04-01 Igryl S Cordero-Hernandez, Alicia C Ross, Arvind Dasari, Daniel M Halperin, Beth Chasen, James C Yao
We observed that some patients with well-differentiated neuroendocrine tumors (NET) who received peptide receptor radionuclide therapy (PRRT) with Lutetium-177 (177Lu) DOTATATE developed rapid disease progression with biopsy-proven histologic transformation to neuroendocrine carcinoma (NEC), an outcome that has not been previously described. Therefore, we conducted a retrospective review of all patients
-
RAB5A polarizes macrophage and promotes breast cancer Endocr. Relat. Cancer (IF 3.9) Pub Date : 2024-03-01 Lei Qiao, Chao Dong, Wenlei Jia, Gang Sun
Breast cancer is the leading cause of cancer-related deaths in females, and triple-negative breast cancer (TNBC) is characterized as one of the main subtypes of breast cancer, with poor prognosis and limited treatments. Investigating the molecular basis or discovering relevant oncogenes will greatly help to develop effective targeted therapies. In this study, we ascertained that RAB5A depletion in
-
HSPB1 promotes tumor invasion by inducing angiogenesis in PitNETs Endocr. Relat. Cancer (IF 3.9) Pub Date : 2024-03-01 Bin Li, Sida Zhao, Yiyuan Chen, Hua Gao, Weiyan Xie, Hongyun Wang, Peng Zhao, Chuzhong Li, Yazhuo Zhang
The clinical diagnosis and treatment of Pituitary neuroendocrine tumors (PitNETs) that invade the cavernous sinus are fraught with difficulties and challenges. Exploring the biological characteristics involved in the occurrence and development of PitNETs that invade the cavernous sinus will help to elucidate the mechanism of cavernous sinus invasion. There are differences between intrasellar tumors
-
Bioengineered in vitro three-dimensional tumor models in endocrine cancers Endocr. Relat. Cancer (IF 3.9) Pub Date : 2024-04-01 Aleksander Skardal, Hemamylammal Sivakumar, Marco A Rodriguez, Liudmila V Popova, Priya H Dedhia
Graphical abstract Abstract Endocrine tumors are a heterogeneous cluster of malignancies that originate from cells that can secrete hormones. Examples include, but are not limited to, thyroid cancer, adrenocortical carcinoma, and neuroendocrine tumors. Many endocrine tumors are relatively slow to proliferate, and as such, they often do not respond well to common antiproliferative chemotherapies. Therefore
-
Efficacy and safety of pralsetinib in Chinese advanced RET-mutant medullary thyroid cancer patients Endocr. Relat. Cancer (IF 3.9) Pub Date : 2024-04-01 Xiangqian Zheng, Meiyu Fang, Yun Fan, Yuping Sun, Meili Sun, Ankui Yang, Bin Zhang, Qinjiang Liu, Hui Liu, Xiaohong Zhou, Tao Huang, Jianwu Qin, Zhaohui Wang, Mengmeng Qin, Zhenwei Shen, Sheng Yao, Jason Yang, Yu Wang, Ming Gao
Pralsetinib has demonstrated efficacious activity in various solid tumors, including medullary thyroid cancer (MTC), as observed in the phase 1/2 global ARROW study (BLU-667-1101; NCT03037385). We evaluated the safety and efficacy of pralsetinib in Chinese patients with advanced RET-mutant MTC. In the extension cohort of ARROW, adult patients with advanced MTC, who had not received systemic therapy
-
Immunotherapy for endocrine tumours: a clinician’s perspective Endocr. Relat. Cancer (IF 3.9) Pub Date : 2024-04-01 Anna Angelousi, Ploutarchos Tzoulis, Marina Tsoli, Eleftherios Chatzellis, Anna Koumarianou, Gregory Kaltsas
Immunotherapy has revolutionised the treatment of oncological patients, but its application in various endocrine tumours is rather limited and is mainly used when conventional therapies have failed. Immune checkpoint inhibitors (ICIs) have been employed in progressive adrenocortical carcinoma, primarily utilizing the anti-PD-L1 agent pembrolizumab, obtaining overall response rates ranging between 14%
-
Lamin B1: a novel biomarker in adult and pediatric adrenocortical carcinoma Endocr. Relat. Cancer (IF 3.9) Pub Date : 2024-03-01 Yihao Chen, Jiahong Chen, Yongcheng Shi, Xiaohui Ling, Shumin Fang, Chuanfan Zhong, Fengping Liu, Weide Zhong, Xuecheng Bi, Zhong Dong, Jianming Lu
Adrenocortical carcinoma (ACC) is a malignancy with a poor prognosis and high mortality rate. A high tumor mutational burden (TMB) has been found to be associated with poor prognosis in ACC. Thus, exploring ACC biomarkers based on TMB holds significant importance for patient risk stratification. In our research, we utilized weighted gene coexpression network analysis and an assay for transposase-accessible
-
Immunophenotyping with high-dimensional flow cytometry identifies Treg cell subsets associated with recurrence in papillary thyroid carcinoma Endocr. Relat. Cancer (IF 3.9) Pub Date : 2024-03-01 Sijin Li, Zhen Chen, Mengchu Liu, Liang Li, Wensong Cai, Zhe-Xiong Lian, Haixia Guan, Bo Xu
The activation of Treg cell subsets is critical for the prognosis of tumor patients; however, their heterogeneity and disease association in papillary thyroid carcinoma (PTC) need further investigation. We performed high-dimensional flow cytometry for immunophenotyping on thyroid tissues and matched peripheral blood samples from patients with multinodular goiters or PTC. We analyzed CD4+ T cell and
-
Alternative schedule of temozolomide/capecitabine in neuroendocrine neoplasms Endocr. Relat. Cancer (IF 3.9) Pub Date : 2024-03-01 Philipp Melhorn, Peter Mazal, Ladislaia Wolff, Petar Popov, Elisabeth Kretschmer-Chott, Alexander Haug, Marius E Mayerhoefer, Markus Raderer, Barbara Kiesewetter
The chemotherapy regimen capecitabine/temozolomide (CAPTEM) is routinely used in neuroendocrine tumors (NET), with antitumor activity particularly demonstrated in pancreatic or high-grade neuroendocrine neoplasms (NEN). However, different dosing regimens are used, and the optimal schedule remains to be defined. This single-center retrospective analysis assessed the efficacy and safety of CAPTEM in
-
Sexual dimorphism in medullary thyroid cancer aggressiveness Endocr. Relat. Cancer (IF 3.9) Pub Date : 2024-03-01 Andreas Machens, Kerstin Lorenz, Frank Weber, Henning Dralle
Thyroid cancer is the only nonreproductive cancer with striking female predominance, although men with thyroid cancer develop more aggressive disease. This study aimed to quantify sex-specific differences in medullary thyroid cancer (MTC) spread after controlling for primary thyroid tumor size. Included in this retrospective analysis were all patients with unilateral solitary MTC who underwent initial
-
Growth hormone and radiation therapy: friend, foe, or both? Endocr. Relat. Cancer (IF 3.9) Pub Date : 2024-03-01 Verónica A Bahamondes Lorca, Shiyong Wu
Radiotherapy is one of the major options currently for cancer treatment. Radiotherapy causes cellular damage inducing cell death, which is expected to be selective for tumor cells. However, side effects that alter the surrounding normal tissue are often hard to be avoided. When radiation involves the hypothalamic–pituitary axis, growth hormone deficiency (GHD) is frequently induced, causing developmental
-
Impact of sex on treatment decisions and outcome in patients with neuroendocrine neoplasms Endocr. Relat. Cancer (IF 3.9) Pub Date : 2024-03-01 Julia Beck, Alexander Siebenhüner, Damian Wild, Emanuel Christ, Julie Refardt
Sex differences affect the management of several diseases in both male and female patients. However, the influence of sex on neuroendocrine neoplasms (NENs) has been scarcely investigated. Thus, this study aimed to compare tumor characteristics, treatment decisions, and overall survival in patients with NENs, stratified by sex. The retrospective analysis of the SwissNET cohort covered NENs of gastroenteropancreatic
-
Beyond the three P’s: adrenal involvement in MEN1 Endocr. Relat. Cancer (IF 3.9) Pub Date : 2024-02-01 Uriel Clemente-Gutierrez, Carolina R C Pieterman, Michael S Lui, Thomas Szabo Yamashita, Andrés Tame-Elorduy, Bernice L Huang, Aditya S Shirali, Derek J Erstad, Jeffrey E Lee, Sarah B Fisher, Paul H Graham, Elizabeth G Grubbs, Steven G Waguespack, Chaan S Ng, Nancy Perrier
Adrenal lesions (ALs) are often detected in patients with multiple endocrine neoplasia type 1 (MEN1). However, they are not well described in MEN1, making their clinical management unclear. This study examined the prevalence and outcomes of ALs found in MEN1. We performed a retrospective chart review of patients diagnosed with MEN1 from 1990 to 2021. ALs were diagnosed using abdominal or thoracic imaging
-
Gender-affirming care and endocrine-related cancers Endocr. Relat. Cancer (IF 3.9) Pub Date : 2024-02-01 Roger Harty, Joshua D Safer
Graphical abstract Abstract With the increasing number of transgender and gender diverse (TGD) individuals who are seeking gender-affirming care, there is a clear need for the development and collection of evidence-based data to establish guidelines for patient care. TGD individuals are estimated to represent 0.3 to 4.5% of the world population. Gender-affirming care that includes hormone therapy helps
-
Genomic profiling of primary and metastatic thyroid cancers Endocr. Relat. Cancer (IF 3.9) Pub Date : 2024-02-01 Valdemar Máximo, Miguel Melo, Yingjie Zhu, Andrea Gazzo, Manuel Sobrinho Simões, Arnaud Da Cruz Paula, Paula Soares
The genetic repertoire of primary thyroid cancers (TCs) is well documented, but there is a considerable lack of molecular profiling in metastatic TCs. Here, we retrieved and analyzed the molecular and clinical features of 475 primary and metastatic TCs subjected to targeted DNA sequencing, from the cBioPortal database. The cohort included primary and metastatic samples from 276 papillary thyroid carcinomas
-
NIFTPs may be reclassified not only from FVPTCs but also from follicular adenomas Endocr. Relat. Cancer (IF 3.9) Pub Date : 2024-02-01 Isabella Albuquerque Pinto Rebello, Vinícius Loures de Oliveira, Luís Felipe Holzwarth Abbud, Tales Aprígio Camargos Ferreira, Ana Paula Aguiar Vidal, Patrícia de Fátima dos Santos Teixeira
Few studies have focused on reclassifying follicular adenomas (FAs) as noninvasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTPs), but none have been conducted in America or Europe. The aims of this study were to analyze the prevalence of NIFTP reclassified from follicular variant of papillary thyroid carcinomas (FVPTCs) and FAs before NIFTP was defined in the literature
-
Steroid profile in patients with breast cancer and in mice treated with mifepristone Endocr. Relat. Cancer (IF 3.9) Pub Date : 2024-02-01 Andres Elía, Leo Saldain, Silvia Lovisi, Paula Martínez Vazquez, Javier Burruchaga, Caroline A Lamb, Isabel Alicia Lüthy, Federico Diez, Natalie Z M Homer, Ruth Andrew, Paola Rojas, Claudia Lanari
Progesterone receptors (PRs) are biomarkers used as prognostic and predictive factors in breast cancer, but they are still not used as therapeutic targets. We have proposed that the ratio between PR isoforms A and B (PRA and PRB) predicts antiprogestin responsiveness. The MIPRA trial confirmed the benefit of 200 mg mifepristone, administered to patients with tumors with a high PRA/PRB ratio, but dose-ranging
-
Survival outcomes for lung neuroendocrine tumors in California differ by sociodemographic factors Endocr. Relat. Cancer (IF 3.9) Pub Date : 2024-01-01 Claire K Mulvey, Alan Paciorek, Farhana Moon, Paige Steiding, Brandon Shih, Matthew A Gubens, Li Zhang, Emily K Bergsland, Iona Cheng
Lung neuroendocrine tumors (NETs) have few known predictors of survival. We investigated associations of sociodemographic, clinicopathologic, and treatment factors with overall survival (OS) and lung cancer-specific survival (LCSS) for incident lung NET cases (typical or atypical histology) in the California Cancer Registry (CCR) from 1992 to 2019. OS was estimated with the Kaplan–Meier method and
-
False-positive results for pheochromocytoma associated with norepinephrine reuptake blockade Endocr. Relat. Cancer (IF 3.9) Pub Date : 2024-01-01 Robin Schürfeld, Christina Pamporaki, Mirko Peitzsch, Nada Rayes, Osama Sabri, Silvio Rohm, Ronald Biemann, Benjamin Sandner, Anke Tönjes, Graeme Eisenhofer
Measurements of plasma metanephrines and methoxytyramine provide a sensitive test for diagnosis of pheochromocytoma/paraganglioma. False-positive results remain a problem, particularly in patients taking norepinephrine reuptake-blocking drugs. Therefore, in this retrospective observational study, we measured plasma metanephrines and methoxytyramine in 61 patients taking norepinephrine reuptake blockers
-
Impact of the PI3K-alpha inhibitor alpelisib on everolimus resistance and somatostatin receptor expression in an orthotopic pancreatic NEC xenograft mouse model Endocr. Relat. Cancer (IF 3.9) Pub Date : 2024-01-01 Ajay-Mohan Mohan, Sonal Prasad, Fabian Schmitz-Peiffer, Catharina Lange, Mathias Lukas, Eva J Koziolek, Jakob Albrecht, Daniel Messroghli, Ulrike Stein, Matthias Ilmer, Katharina Wang, Laura Schober, Astrid Reul, Julian Maurer, Juliane Friemel, Achim Weber, Richard A Zuellig, Constanze Hantel, Ralph Fritsch, Martin Reincke, Karel Pacak, Ashley B Grossman, Christoph J Auernhammer, Felix Beuschlein,
The mechanistic target of rapamycin complex 1 (mTORC1) inhibitor everolimus is one of the few approved therapies for locally advanced and metastatic neuroendocrine tumours (NETs). However, after initial disease stabilisation, most patients develop resistance within 1 year. Our aim was to overcome resistance to everolimus by additional treatment with the PI3K-alpha inhibitor alpelisib in an everolimus-resistant
-
Core needle biopsy in pheochromocytoma/paraganglioma: should it be considered? Endocr. Relat. Cancer (IF 3.9) Pub Date : 2023-11-30 Gergely Huszty,Peter Igaz
-
Response to Letter to the Editor regarding 'Risk of complications after core needle biopsy in pheochromocytoma/paraganglioma'. Endocr. Relat. Cancer (IF 3.9) Pub Date : 2023-11-30 Liang Zhang,Tobias Åkerström,Kazhan Mollazadegan,Felix Beuschlein,Karel Pacak,Britt Skogseid,Joakim Crona
-
Autocrine/paracrine growth hormone in cancer progression Endocr. Relat. Cancer (IF 3.9) Pub Date : 2024-01-01 Xi Zhang, Vijay Pandey, Vipul Bhardwaj, Tao Zhu, Peter E Lobie
Abstract It is now apparent that growth hormone (GH), an anterior pituitary hormone predominantly regulating postnatal somatic growth and metabolism, is also expressed in extrapituitary tissues. An extrapituitary synthetic site of GH that has garnered interest is the de novo or enhanced expression of GH in carcinoma or other cancers. In a number of cancers, including carcinoma of the mammary gland
-
Сytotoxic T lymphocyte-associated protein 4 (CTLA4) is overexpressed in a subset of prolactin- and growth hormone-secreting pituitary adenomas Endocr. Relat. Cancer (IF 3.9) Pub Date : 2024-01-01 Elena Sabini, Amna Khan, Patrizio Caturegli
Cytotoxic T lymphocyte-associated protein 4 (CTLA4), a negative regulator typically expressed on the surface of T lymphocytes, is targeted by immunotherapy in patients with an ever-expanding spectrum of cancers. Characterizing the expression of CTLA4 in the pituitary gland could provide additional rationale for using immune checkpoint inhibitors in pituitary adenoma patients who do not respond to conventional
-
Mammary gland development and EDC-driven cancer susceptibility in mesenchymal ERα-knockout mice Endocr. Relat. Cancer (IF 3.9) Pub Date : 2023-12-01 Clarissa Wormsbaecher, Brittney M Cumbia, Emma G Amurgis, Jillian M Poska, Madeline R Price, Xiaokui M Mo, Sue E Knoblaugh, Takeshi Kurita, Craig Joseph Burd
Development of the mammary gland requires both proper hormone signaling and cross talk between the stroma and epithelium. While estrogen receptor (ERα) expression in the epithelium is essential for normal gland development, the role of this receptor in the stroma is less clear. Moreover, several lines of evidence suggest that mouse phenotypes of in utero exposure to endocrine disruption act through
-
Semaphorin 3C promotes de novo steroidogenesis in prostate cancer cells Endocr. Relat. Cancer (IF 3.9) Pub Date : 2023-12-01 Parvin Yenki, Satyam Bhasin, Liang Liu, Noushin Nabavi, Chi Wing Cheng, Kevin J Tam, James W Peacock, Hans H Adomat, Tabitha Tombe, Ladan Fazli, Larissa Ivanova, Christopher Dusek, Shahram Khosravi, Emma S Tomlinson Guns, Yuzhuo Wang, Ralph Buttyan, Martin E Gleave, Christopher J Ong
Intratumoral androgen biosynthesis contributes to castration-resistant prostate cancer progression in patients treated with androgen deprivation therapy. The molecular mechanisms by which castration-resistant prostate cancer acquires the capacity for androgen biosynthesis to bypass androgen deprivation therapy are not entirely known. Here, we show that semaphorin 3C, a secreted signaling protein that
-
Regulation of epinephrine biosynthesis in HRAS-mutant paragangliomas Endocr. Relat. Cancer (IF 3.9) Pub Date : 2023-12-01 Minghao Li, Susan Richter, Hermine Mohr, Stephan Drukewitz, Isabel Poser, Daniela Stanke, Bruna Calsina, Angel M Martinez-Montes, Marcus Quinkler, Henri J L M Timmers, Svenja Nölting, Felix Beuschlein, Hanna Remde, Giuseppe Opocher, Elena Rapizzi, Karel Pacak, Christina Pamporaki, Mercedes Robledo, Longfei Liu, Jingjing Jiang, Stefan R Bornstein, Graeme Eisenhofer, Stephanie M J Fliedner, Nicole Bechmann
The biochemical phenotype of paragangliomas (PGLs) is highly dependent on the underlying genetic background and tumor location. PGLs at extra-adrenal locations usually do not express phenylethanolamine N-methyltransferase (PNMT), the enzyme required for epinephrine production, which was explained by the absence of glucocorticoids. PGLs with pathogenic variants (PVs) in Harvey rat sarcoma viral oncogene
-
Therapeutic inhibition of ATR in differentiated thyroid cancer Endocr. Relat. Cancer (IF 3.9) Pub Date : 2023-12-01 Shu-Fu Lin, Yi-Yin Lee, Ming-Hsien Wu, Yu-Ling Lu, Chun-Nan Yeh, Wei-Yi Chen, Ting-Chao Chou, Richard J Wong
Ataxia telangiectasia and Rad3-related protein (ATR) is a critical component of the DNA damage response and a potential target in the treatment of cancers. An ATR inhibitor, BAY 1895344, was evaluated for its use in differentiated thyroid cancer (DTC) therapy. BAY 1895344 inhibited cell viability in four DTC cell lines (TPC1, K1, FTC-133, and FTC-238) in a dose-dependent manner. BAY 1895344 treatment
-
Liquid biopsies in thyroid cancers: a systematic review and meta-analysis Endocr. Relat. Cancer (IF 3.9) Pub Date : 2023-12-01 Walid Zeyghami, Marie-Louise Uhre Hansen, Kathrine Kronberg Jakobsen, Christian Groenhøj, Ulla Feldt-Rasmussen, Christian von Buchwald, Christoffer Holst Hahn
Thyroid cancer (TC) represents the most common endocrine malignant tumor. Liquid biopsy has been suggested as a new and accurate biomarker in cancer. This systematic review analyzes the existing literature on circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA integrity index (cfDI), and their potential as biomarkers for TC, including the subtypes: differentiated (papillary
-
RET fusion genes in pediatric and adult thyroid carcinomas: cohort characteristics and prognosis Endocr. Relat. Cancer (IF 3.9) Pub Date : 2023-12-01 Barbora Bulanova Pekova, Vlasta Sykorova, Karolina Mastnikova, Eliska Vaclavikova, Jitka Moravcova, Petr Vlcek, Lucie Lancova, Petr Lastuvka, Rami Katra, Petr Bavor, Daniela Kodetova, Martin Chovanec, Jana Drozenova, Radoslav Matej, Jaromir Astl, Jiri Hlozek, Petr Hrabal, Josef Vcelak, Bela Bendlova
Thyroid cancer is associated with a broad range of different mutations, including RET (rearranged during transfection) fusion genes. The importance of characterizing RET fusion-positive tumors has recently increased due to the possibility of targeted treatment. The aim of this study was to identify RET fusion-positive thyroid tumors, correlate them with clinicopathological features, compare them with
-
Cabozantinib in neuroendocrine tumors: tackling drug activity and resistance mechanisms Endocr. Relat. Cancer (IF 3.9) Pub Date : 2023-12-01 Chiara Alessandra Cella, Riccardo Cazzoli, Nicola Fazio, Giuseppina De Petro, Germano Gaudenzi, Silvia Carra, Mauro Romanenghi, Francesca Spada, Ilaria Grossi, Isabella Pallavicini, Saverio Minucci, Giovanni Vitale
Neuroendocrine tumors (NETs) are highly vascularized malignancies in which angiogenesis may entail cell proliferation and survival. Among the emerging compounds with antivascular properties, cabozantinib (CAB) appeared promising. We analyzed the antitumor activity of CAB against NETs utilizing in vitro and in vivo models. For cell cultures, we used BON-1, NCI-H727 and NCI-H720 cell lines. Cell viability
-
ThyroidPrint®: clinical utility for indeterminate thyroid cytology Endocr. Relat. Cancer (IF 3.9) Pub Date : 2023-11-01 Roberto Olmos, José Miguel Domínguez, Sergio Vargas-Salas, Lorena Mosso, Carlos E Fardella, Gilberto González, René Baudrand, Francisco Guarda, Felipe Valenzuela, Eugenio Arteaga, Pablo Forenzano, Flavia Nilo, Nicole Lustig, Alejandra Martínez, José M López, Francisco Cruz, Soledad Loyola, Augusto Leon, Nicolás Droppelmann, Pablo Montero, Francisco Domínguez, Mauricio Camus, Antonieta Solar, Pablo
Molecular testing contributes to improving the diagnosis of indeterminate thyroid nodules (ITNs). ThyroidPrint® is a ten-gene classifier aimed to rule out malignancy in ITN. Post-validation studies are necessary to determine the real-world clinical benefit of ThyroidPrint® in patients with ITN. A single-center, prospective, noninterventional clinical utility study was performed, analyzing the impact
-
Hypoxia-associated genetic signature in ovarian steroid cell tumor NOS Endocr. Relat. Cancer (IF 3.9) Pub Date : 2023-11-01 Angel Chao, Huei-Jean Huang, Chiao-Yun Lin, Chia-Hwa Lee, Chien-Hsing Lin, An-Shine Chao, Chyong-Huey Lai, Ting-Chang Chang, Kai-Yun Wu, Ren-Chin Wu
Steroid cell tumors, not otherwise specified (SCT-NOS), are uncommon ovarian neoplasms accompanied by virilization symptoms due to hyperandrogenism, which are malignant in approximately one-third of the cases. Given the rarity of SCT-NOS, their molecular underpinnings have not yet been studied in depth. In this case series, we performed the first comprehensive analysis of the genetic landscape of this
-
IGF-1 axis changes with ADT and docetaxel in metastatic prostate cancer Endocr. Relat. Cancer (IF 3.9) Pub Date : 2023-11-01 Praful Ravi, Victoria Wang, Raina N Fichorova, Bradley McGregor, Xiao X Wei, Shehzad Basaria, Christopher J Sweeney
Androgen deprivation therapy (ADT) forms the cornerstone of treatment in locally advanced and metastatic prostate cancer (PCa). Since the growth hormone–insulin-like growth factor (GH–IGF-1) axis has been implicated in prostate tumorigenesis, we aimed to evaluate the association between IGF-1 and its binding proteins on outcomes in men with metastatic PCa treated with ADT, with or without docetaxel
-
MicroRNA regulation of the serine synthesis pathway in endocrine-resistant breast cancer cells Endocr. Relat. Cancer (IF 3.9) Pub Date : 2023-11-01 Belinda J Petri, Kellianne M Piell, Ali E Wilt, Alexa D Howser, Laura Winkler, Mattie R Whitworth, Bailey L Valdes, Norman L Lehman, Brian F Clem, Carolyn M Klinge
Despite the successful combination of therapies improving survival of estrogen receptor α (ER+) breast cancer patients with metastatic disease, mechanisms for acquired endocrine resistance remain to be fully elucidated. The RNA binding protein HNRNPA2B1 (A2B1), a reader of N(6)-methyladenosine (m6A) in transcribed RNA, is upregulated in endocrine-resistant, ER+ LCC9 and LY2 cells compared to parental
-
Vemurafenib activates the sonic hedgehog pathway and promotes thyroid cancer stem cell self-renewal Endocr. Relat. Cancer (IF 3.9) Pub Date : 2023-11-01 Yurong Lu, Yuqing Zhao, Penggang Liu, Xiulong Xu
B-Raf kinase inhibitors such as vemurafenib (PLX4032) and dabrafenib have limited therapeutic efficacy on BRAF-mutated thyroid cancer. Cancer stem cells (CSCs) play important roles in tumor recurrence, drug resistance, and metastasis. Whether CSCs play a role in dampening the antitumor activity of B-Raf kinase inhibitors remains unknown. Here, we report that vemurafenib (PLX4032) induced the expression
-
A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors Endocr. Relat. Cancer (IF 3.9) Pub Date : 2023-11-01 Sonia M Abuzakhm, Vineeth Sukrithan, Briant Fruth, Rui Qin, Jonathan Strosberg, Timothy J Hobday, Thomas Semrad, Diane Reidy-Lagunes, Hedy Lee Kindler, George P Kim, Jennifer J Knox, Andreas Kaubisch, Miguel Villalona-Calero, Helen Chen, Charles Erlichman, Manisha H Shah
We assessed the efficacy and safety of combining bevacizumab with temsirolimus in patients with advanced extra-pancreatic neuroendocrine tumors. This NCI-sponsored multicenter, open-label, phase II study (NCT01010126) enrolled patients with advanced, recurrent, or metastatic extra-pancreatic neuroendocrine tumors. All patients were treated with temsirolimus and bevacizumab until disease progression
-
Insulin-like growth factor-1 receptor crosstalk with integrins, cadherins, and the tumor microenvironment: sticking points in understanding IGF1R function in cancer Endocr. Relat. Cancer (IF 3.9) Pub Date : 2023-10-01 Christopher A Galifi, Teresa L Wood
Despite decades of research presenting insulin-like growth factor-1 receptor (IGF1R) as an attractive target for cancer therapy, IGF1R inhibitors ultimately failed in clinical trials. This was surprising due to the known cancer-promoting functions of IGF1R, including stimulation of cell invasion, proliferation, and survival. Discourse in the literature has acknowledged that a lack of patient stratification
-
The aggressiveness of succinate dehydrogenase subunit B-deficient chromaffin cells is reduced when their bioelectrical properties are restored by glibenclamide Endocr. Relat. Cancer (IF 3.9) Pub Date : 2023-10-01 Francesca Amore, Rachele Garella, Alice Santi, Daniele Guasti, Serena Martinelli, Letizia Canu, Daniele Bani, Jiri Neuzil, Mario Maggi, Roberta Squecco, Elena Rapizzi
Pheochromocytomas/paragangliomas (PPGLs) are neuroendocrine tumours, mostly resulting from mutations in predisposing genes. Mutations of succinate dehydrogenase (SDH) subunit B (SDHB) are associated with high probability of metastatic disease. Since bioelectrical properties and signalling in cancer are an emerging field, we investigated the metabolic, functional and electrophysiological characteristics
-
Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms Endocr. Relat. Cancer (IF 3.9) Pub Date : 2023-10-01 Andreas Venizelos, Halfdan Sorbye, Hege Elvebakken, Aurel Perren, Inger Marie B Lothe, Anne Couvelard, Geir Olav Hjortland, Anna Sundlöv, Johanna Svensson, Harrish Garresori, Christian Kersten, Eva Hofsli, Sönke Detlefsen, Lene W Vestermark, Morten Ladekarl, Elizaveta Mitkina Tabaksblat, Stian Knappskog
High-grade gastroenteropancreatic (HG-GEP) neuroendocrine neoplasms (NENs) are highly aggressive cancers. The molecular etiology of these tumors remains unclear, and the prevalence of pathogenic germline variants in patients with HG-GEP NENs is unknown. We assessed sequencing data of 360 cancer genes in normal tissue from 240 patients with HG-GEP NENs; 198 patients with neuroendocrine carcinomas (NECs)
-
Pacak–Zhuang syndrome: a model providing new insights into tumor syndromes Endocr. Relat. Cancer (IF 3.9) Pub Date : 2023-10-01 Jared S Rosenblum, Herui Wang, Matthew A Nazari, Zhengping Zhuang, Karel Pacak
This article is a summary of the plenary lecture presented by Jared Rosenblum that was awarded the Manger Prize at the Sixth International Symposium on Pheochromocytoma/Paraganglioma held on 19–22 October 2022 in Prague, Czech Republic. Herein, we review our initial identification of a new syndrome of multiple paragangliomas, somatostatinomas, and polycythemia caused by early postzygotic mosaic mutations
-
DIPNECH: pragmatic approach, uncertainties, notable associations, and a proposal for an improved definition Endocr. Relat. Cancer (IF 3.9) Pub Date : 2023-10-01 Bilal F Samhouri, Thorvardur R Halfdanarson, Chi Wan Koo, Cormac McCarthy, Eunhee S Yi, Charles F Thomas, Jay H Ryu
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a rare, but increasingly recognized entity that primarily affects middle-aged and elderly women. It is characterized by abnormal proliferation of pulmonary neuroendocrine cells (PNECs) and is considered a preinvasive lesion for carcinoid tumorlets/tumors. Sometimes, DIPNECH is accompanied by constrictive bronchiolitis which usually
-
Detection and yield of thyroid cancer surveillance in adults with PTEN hamartoma tumour syndrome Endocr. Relat. Cancer (IF 3.9) Pub Date : 2023-10-01 Meggie M C M Drissen, Janet R Vos, Romana T Netea-Maier, Martin Gotthardt, Nicoline Hoogerbrugge
Thyroid cancer surveillance (TCS) with ultrasound (US) is advised for PTEN hamartoma tumour syndrome (PHTS) patients due to increased thyroid cancer (TC) risk. However, data supporting TCS guidelines are scarce. We aimed to assess the detection and yield of annual TCS with US in adult PHTS patients without a TC history and to evaluate the impact of a reduced US interval on the TCS yield. A retrospective
-
Cancer in growth hormone excess and growth hormone deficit Endocr. Relat. Cancer (IF 3.9) Pub Date : 2023-10-01 Jaime Guevara-Aguirre, Gabriela Peña, William Acosta, Gabriel Pazmiño, Jannette Saavedra, Lina Soto, Daniela Lescano, Alexandra Guevara, Antonio W D Gavilanes
The relationship between growth hormone (GH) excess and cancer is a controversial matter. Until 2016, most studies in patients with acromegaly found links with colon and thyroid neoplasms. However, recent studies found increased risks in gastric, breast, and urinary tract cancer also. Concordantly, clinical situations where GH and insulin-like growth facto-I deficits exist are indeed associated with
-
The roles of anti-Müllerian hormone in breast cancer Endocr. Relat. Cancer (IF 3.9) Pub Date : 2023-10-01 Xuan Chen, Sixuan Liu, Xue Peng, Xiangyun Zong
Anti-Müllerian hormone (AMH) is produced and secreted by granulosa cells of growing follicles, and its main role is to inhibit the recruitment of primordial follicles, reduce the sensitivity of follicles to follicle-stimulating hormone (FSH), and regulate FSH-dependent preantral follicle growth. It has become an effective indicator of ovarian reserve in clinical practice. Research on AMH and its receptors
-
Multimodal treatment for resectable neuroendocrine carcinoma of the cervix Endocr. Relat. Cancer (IF 3.9) Pub Date : 2023-10-01 Carmine Valenza, Francesca Spada, Francesco Multinu, Lavinia Benini, Michele Borghesani, Laura Algeri, Manila Rubino, Eleonora Pisa, Lorenzo Gervaso, Chiara Alessandra Cella, Silvestro Carinelli, Simone Bruni, Gabriella Schivardi, Giuseppe Curigliano, Vanna Zanagnolo, Giovanni Aletti, Nicoletta Colombo, Nicola Fazio
Non-metastatic neuroendocrine carcinoma of the cervix (NECC) is a rare and aggressive disease. Lacking prospective studies, the optimal multimodal treatment approach has not yet been clearly defined. This study aims to assess the clinical outcomes of patients with non-metastatic NECC treated with surgery and (neo)adjuvant chemotherapy, according to pathologic prognostic factors and multimodal treatments
-
Emerging therapies for advanced insulinomas and glucagonomas Endocr. Relat. Cancer (IF 3.9) Pub Date : 2023-09-01 Krystallenia I Alexandraki, Gregory A Kaltsas, Simona Grozinsky-Glasberg
Pancreatic neuroendocrine neoplasms (panNENs) are rare relatively malignancies that, despite their frequently slow-growing pattern, have the ability to metastasize. Metastatic and/or advanced insulinomas and glucagonomas are functioning panNENs emerging from the pancreas displaying unique peculiarities, depending on their hormonal syndromes and increased malignant potential. Advanced insulinomas management
-
A clinically applicable molecular classification of oncocytic cell thyroid nodules Endocr. Relat. Cancer (IF 3.9) Pub Date : 2023-09-01 Elizabeth J de Koster, Willem E Corver, Lioe-Fee de Geus-Oei, Wim J G Oyen, Dina Ruano, Abbey Schepers, Marieke Snel, Tom van Wezel, Dennis Vriens, Hans Morreau
Whole chromosome instability with near-whole genome haploidization (GH) and subsequent endoreduplication is considered a main genomic driver in the tumorigenesis of oncocytic cell thyroid neoplasms (OCN). These copy number alterations (CNA) occur less frequently in oncocytic thyroid adenoma (OA) than in oncocytic carcinoma (OCA), suggesting a continuous process. The current study described the CNA
-
Lymphangioleiomyomatosis: where endocrinology, immunology and tumor biology meet Endocr. Relat. Cancer (IF 3.9) Pub Date : 2023-09-01 Erin Gibbons, Briaunna M N Minor, Stephen R Hammes
Graphical abstract Abstract Lymphangioleiomyomatosis (LAM) is a cystic lung disease found almost exclusively in genetic females and caused by small clusters of smooth muscle cell tumors containing mutations in one of the two tuberous sclerosis genes (TSC1 or TSC2). Significant advances over the past 2–3 decades have allowed researchers and clinicians to more clearly understand the pathophysiology of
-
Chromosomal alterations in sporadic medullary thyroid carcinoma and correlation with outcome Endocr. Relat. Cancer (IF 3.9) Pub Date : 2023-09-01 Teresa Ramone, Cristina Romei, Raffaele Ciampi, Roberta Casalini, Angelo Valetto, Veronica Bertini, Francesco Raimondi, Anthony Onoja, Alessandro Prete, Antonio Matrone, Carla Gambale, Paolo Piaggi, Liborio Torregrossa, Clara Ugolini, Rossella Elisei
Somatic copy number alterations (SCNA) involving either a whole chromosome or just one of the arms, or even smaller parts, have been described in about 88% of human tumors. This study investigated the SCNA profile in 40 well-characterized sporadic medullary thyroid carcinomas by comparative genomic hybridization array. We found that 26/40 (65%) cases had at least one SCNA. The prevalence of SCNA, and
-
Whole-exome sequencing of rectal neuroendocrine tumors Endocr. Relat. Cancer (IF 3.9) Pub Date : 2023-09-01 Yuanliang Li, Yiying Guo, Zixuan Cheng, Chao Tian, Yingying Chen, Ruao Chen, Fuhuan Yu, Yanfen Shi, Fei Su, Shuhua Zhao, Zhizheng Wang, Jie Luo, Huangying Tan
The genetic characteristics of rectal neuroendocrine tumors (R-NETs) were poorly understood. Depicting the genetic characteristics may provide a biological basis for prognosis prediction and novel treatment development. Tissues of 18 R-NET patients were analyzed using whole-exome sequencing. The median tumor mutation burden (TMB) and microsatellite instability (MSI) were 1.15 Muts/MB (range, 0.03–23
-
Autophagic blockade potentiates anlotinib-mediated ferroptosis in anaplastic thyroid cancer Endocr. Relat. Cancer (IF 3.9) Pub Date : 2023-09-01 Jiajun Wu, Juyong Liang, Ruiqi Liu, Tian Lv, Kangyin Fu, Liehao Jiang, Wenli Ma, Yan Pan, Zhuo Tan, Qing Liu, Weihua Qiu, Minghua Ge, Jiafeng Wang
Anlotinib-mediated angiogenic remodeling was delineated in various tumors. Meanwhile, we previously showed that anlotinib inhibited tumor angiogenesis in anaplastic thyroid cancer (ATC). However, the potential role of anlotinib on cell lethality in ATC remains an enigma. Herein, we found that anlotinib inhibited the viability, proliferation, and migration of KHM-5M, C643, and 8505C cells in a dose-dependently
-
Intratumor microbiota modulates adrenocortical cancer responsiveness to mitotane Endocr. Relat. Cancer (IF 3.9) Pub Date : 2023-08-01 Giulia Cantini, Elena Niccolai, Letizia Canu, Leandro Di Gloria, Simone Baldi, Arianna Pia Propato, Laura Fei, Giulia Nannini, Soraya Puglisi, Gabriella Nesi, Matteo Ramazzotti, Amedeo Amedei, Michaela Luconi
The infiltrating microbiota represents a novel cellular component of solid tumor microenvironment that can influence tumour progression and response to therapy. Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine malignancy for which mitotane (MTT) treatment represents the first line therapy, though its efficacy is limited to a therapeutic window level (14-20mg/L). Novel markers able
-
Embryonic stem cell factor FOXD3 (Genesis) defects in gastrointestinal stromal tumors Endocr. Relat. Cancer (IF 3.9) Pub Date : 2023-08-01 Fabio R Faucz, Anelia D. Horvath, Guillaume Assié, Madson Q Almeida, Eva Szarek, Sosipatros Boikos, Anna Angelousi, Isaac Levy, Andrea G Maria, Ajay Chitnis, Cristina Antonescu, Rainer Claus, Jérôme Bertherat, Christoph Plass, Charis Eng, Constantine A Stratakis
Gastrointestinal stromal tumors (GIST) are mesenchymal neoplasms, believed to originate from the interstitial cells of Cajal (ICC), often caused by overexpression of tyrosine kinase receptors (TKR) KIT or PDGFRA. Here, we present evidence that the embryonic stem cell factor FOXD3, first identified as “Genesis” and functioning in both gastrointestinal and neural crest cell development, is implicated
-
GH and IGF1 in cancer therapy resistance Endocr. Relat. Cancer (IF 3.9) Pub Date : 2023-09-01 Reetobrata Basu, John J Kopchick
Despite landmark advances in cancer treatments over the last 20 years, cancer remains the second highest cause of death worldwide, much ascribed to intrinsic and acquired resistance to the available therapeutic options. In this review, we address this impending issue, by focusing the spotlight on the rapidly emerging role of growth hormone action mediated by two intimately related tumoral growth factors
-
Targeting growth hormone in cancer: future perspectives Endocr. Relat. Cancer (IF 3.9) Pub Date : 2023-09-01 Yue Wang, Stephen M F Jamieson, Jo K Perry
Decades of published research support a role for growth hormone (GH) in cancer. Accordingly, there is increasing interest in targeting GH in oncology, with GH antagonists exhibiting efficacy in xenograft studies as single agents and in combination with anticancer therapy or radiation. Here we discuss challenges associated with using growth hormone receptor (GHR) antagonists in preclinical models and